The company claimed that the body has a specific gene to produce an ergothioneine transporter.
It also claimed that the L-ergothioneine has shown specific promise in extending healthy lifespans, cognitive function, and lung and heart health.
An independent panel of experts reached a decision after a review of the safety, toxicology and proposed usage of Oxis’ synthetic L-ergothioneine that it is safe for use in dietary supplements, food and beverage products.
Oxis CEO David Saloff said achieving GRAS status for their L-ergothioneine opens the door wide to significant new commercial opportunities for the company including the multi-billion dollar market segment for functional foods and beverages.